Literature DB >> 6437441

Complete amino acid sequence of the heavy-chain variable region from an A/J mouse antigen-nonbinding monoclonal antibody bearing the predominant arsonate idiotype.

J A Smith, M N Margolies.   

Abstract

The 1F6 hybridoma protein, exhibiting the predominant cross-reactive idiotype (CRI) associated with the immune response to p-azophenylarsonate in A/J mice but failing to bind the hapten arsonate, was elicited following immunization with rat anti-CRI [Wysocki, L.J., & Sato, V. (1981) Eur. J. Immunol. 11, 832-839]. The dissociation of idiotype and antigen binding in this hybridoma provides an opportunity to determine structural features involved in antigen binding and idiotypic sites. The complete heavy-chain variable region (VH) amino acid sequence was obtained by automated Edman degradation of the intact chain and fragments due to CNBr cleavage, trypsin digestion, mild acid hydrolysis, and carboxypeptidase A digestion of a CNBr fragment. Comparison of the CRI+ arsonate-nonbinding 1F6 sequence with the CRI+ germ-line VH gene sequence reveals that the 1F6 heavy chain differs from the germ-line-encoded amino acid sequence at seven positions within VH [Siekevitz, M., Gefter, M. L., Brodeur, P., Riblet, R., & Marshak-Rothstein, A. (1982) Eur. J. Immunol. 12, 1023-1032]. The 1F6 VH appears to arise from the CRI+ germ-line VH by somatic mutation at at least seven amino acid residues, each of which could be due to a single nucleotide base change. The diversity (D) gene-encoded segment of 1F6 is similar to that of the CRI+ antigen-binding hybridoma 36-65 except for two amino acid substitutions. Further, the idiotype (CRI) is preserved despite use of a JH4 gene segment in 1F6 as compared to JH2 in all CRI+ arsonate-binding hybridomas examined to date.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437441     DOI: 10.1021/bi00315a031

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Identity of the V kappa 10-Ars-A gene segments of the A/J and BALB/c strains.

Authors:  K Meek; I Sanz; G Rathbun; A Nisonoff; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

2.  An unusual bovine pancreatic protein exhibiting pH-dependent globule-fibril transformation and unique amino acid sequence.

Authors:  J Gross; A W Brauer; R F Bringhurst; C Corbett; M N Margolies
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

3.  Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies.

Authors:  D J Panka; M Mudgett-Hunter; D R Parks; L L Peterson; L A Herzenberg; E Haber; M N Margolies
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.

Authors:  J F Schildbach; S Y Shaw; R E Bruccoleri; E Haber; L A Herzenberg; G C Jager; P D Jeffrey; D J Panka; D R Parks; R I Near
Journal:  Protein Sci       Date:  1994-05       Impact factor: 6.725

5.  Isolation, characterization, and distribution of an unusual pancreatic human secretory protein.

Authors:  J Gross; R I Carlson; A W Brauer; M N Margolies; A L Warshaw; J R Wands
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

6.  Somatically mutated forms of a major anti-p-azophenylarsonate antibody variable region with drastically reduced affinity for p-azophenylarsonate. By-products of an antigen-driven immune response?

Authors:  T Manser; B Parhami-Seren; M N Margolies; M L Gefter
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

7.  Parallel evolution of antibody variable regions by somatic processes: consecutive shared somatic alterations in VH genes expressed by independently generated hybridomas apparently acquired by point mutation and selection rather than by gene conversion.

Authors:  L J Wysocki; M L Gefter; M N Margolies
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.